Theranos Faces Rare Pre-IPO Securities Class Action
Hagens Berman partner Reid Kathrein, who filed the suit, said private investors sank more than $600 million into the beleaguered blood-testing startup based on false claims about its technology.
This premium content is reserved for The Recorder subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now